NUP98 and acute myeloid leukemia: Until August 2019, over 25 nanoparticle treatments have been approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) for clinical use, which underscores the translational potential of our study for the treatment of NUP98-NSD1-positive AML patients [50].